24
Participants
Start Date
July 1, 2018
Primary Completion Date
April 1, 2019
Study Completion Date
April 1, 2019
Trimetazidine
Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in \>80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several-not yet fully understood-mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).
The University of the West Indies, Saint Augustine
The University of The West Indies
OTHER